Clinical Trial

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail/frail patients with probable/proven pancreaticobiliary, ovarian, kidney, or bladder cancer prior to elective major cancer surgery (EMCS).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-25; most recent amendment 2026-03-10.
Status change: Not Yet Recruiting → Recruiting 2026-03-10
Trial Details
NCT Number NCT07050771
Lead Sponsor The Methodist Hospital Research Institute
Conditions Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa), Kidney Cancers, Bladder Cancer
Enrollment 148 participants
Start Date 2025-08-14
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-12